Zhejiang CONBA Pharmaceutical Co., Ltd. Class A

Zhejiang CONBA Pharmaceutical Co., Ltd. Class A

SSSE:600572
4.18
CNY
+0.01
(+0.24%)
0.19EPS
23.96P/E
10.95BMarket Cap
Apr 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.43
1.73
2.29
2.46
2.08
2.67
2.55
2.35
2.54
2.35
2.62
2.62
2.59
2.69
Basic EPS, GAAP
0.2
0.27
0.19
0.18
0.28
0.31
-0.13
0.18
0.78
0.14
0.23
0.25
0.19
0.18
Free Cash Flow per Basic Share
-0.12
0.09
0.23
0.3
0.17
0.06
0.25
0.31
0.12
0.34
0.27
0.29
0.32
- -
Dividend per Share
0.08
0.11
0.16
0.12
0.13
0.18
0.2
0.06
0.03
0.19
0.16
0.21
0.15
0.15
Book Value per Share
1.15
1.35
1.65
1.71
2.28
2.13
1.75
1.88
2.8
2.69
2.74
2.64
2.78
2.86
Tangible Book Value per Share
0.9
0.66
0.99
1.16
1.73
1.61
1.51
1.68
2.58
2.47
2.52
2.42
2.56
2.65
Basic Weighted Avg Shares
2,047
2,071
2,318
2,450
2,540
2,630
2,659
2,518
2,586
2,558
2,572
2,490
2,497
2,539
Sales/Revenue/Turnover
2,924
3,582
5,302
6,020
5,294
7,018
6,768
5,909
6,568
6,000
6,733
6,515
6,473
6,828
Operating Margin (%)
14.54
18.39
16.57
12.71
19.26
16.63
15.39
12.48
13.39
13.09
12.55
10.96
9.64
12.01
Depreciation Expense
100
128
174
230
217
241
261
266
287
277
324
345
345
- -
Net Income, GAAP
417
552
440
441
711
815
-346
453
2,017
358
592
622
474
457
Effective Tax Rate (%)
17.89
14.53
17.49
24.39
18.54
20.55
- -
28.27
15.48
22.02
12.11
15.59
23.81
26.28
Profit Margin (%)
14.27
15.42
8.31
7.33
13.43
11.62
-5.11
7.67
30.72
5.97
8.79
9.55
7.33
6.69
Working Capital
1,138
332
710
1,124
2,336
1,258
502
882
2,298
2,606
2,603
1,902
2,120
2,367
LT Debt
654
904
532
1,134
1,110
1,258
511
507
13
334
306
120
41
21
Total Equity
2,592
3,370
4,565
4,488
5,844
5,856
4,943
5,349
7,635
7,324
7,350
6,913
7,152
7,376
Return on Invested Capital (%)
10.44
15.33
7.59
5.3
10.47
10.33
- -
7.26
25.14
5.27
8.11
8.5
6.88
6.63
Return on Capital (%)
11.78
10.28
8.03
8.3
10.72
11.15
- -
5.81
23.28
3.34
6.39
7.68
6.26
5.93
Return on Common Equity (%)
18.38
21.42
12.71
10.44
14.17
14.27
-6.68
9.36
33
5.07
8.48
8.98
6.84
6.49

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
107
93
169
LT Borrowings
40
20
20
LT Finance Leases
3
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,537
2,539
2,540
Market Capitalization
11,162
9,951
10,948

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,881
4,935
5,091
Cash, Cash Equivalents & STI
856
905
882
Accounts Receivable, Net
1,326
1,441
1,455
Inventories
1,087
1,104
1,085
Total Current Liabilities
2,461
2,619
2,725
Payables & Accruals
- -
- -
- -
ST Debt
107
93
169
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.79%
7.3%
3.46%
Free Cash Flow
37.19%
22.55%
10.17%
Net Income, GAAP
1.19%
61.88%
-23.79%
Sales/Revenue/Turnover
2.86%
2.17%
-0.64%
Total Cash Common Dividend
39.52%
83.98%
-26.72%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,824
1,624
1,465
1,602
6,515
2025
1,685
1,674
- -
1,498
6,473
2026
1,906
1,796
1,629
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.07
0.05
0.04
0.25
2025
0.08
0.07
- -
-0.04
0.19
2026
0.08
0.07
0.07
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.2
- -
- -
0.21
2025
- -
0.15
- -
- -
0.15
2026
- -
0.15
- -
- -
- -

Company Description

CEO
Yi Jiang
Full Time Employees
7,826
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Binjiang Science and Technology Economic Park Hangzhou ZH China 310051
IPO Date
Apr 12, 2004
Business
Zhejiang CONBA Pharmaceutical Co., Ltd. (600572.SS) engages in the research, development, manufacturing, and sales of traditional Chinese medicines, modern phytomedicines, chemical drugs, and active pharmaceutical ingredients primarily in China. The company offers an extensive range of products including Chinese herbal decoction pieces and patent medicines; chemical pharmaceutical preparations and raw materials; biological products and medical devices; and diverse dosage forms such as tablets, capsules, pills, dripping pills, granules, powders, injections, freeze-dried powder injections, oral liquids, syrups, nasal drops, eye drops, ear drops, and ointments, targeting therapeutic areas like cardiovascular and cerebrovascular diseases, urinary system disorders, digestive conditions, respiratory illnesses, endocrine and nervous system ailments, and anti-infectives. Founded in 1969 as Lanxi Yunshan Pharmaceutical Factory and renamed in 1999, it is headquartered at 568 Binkang Road, Binjiang Sci & Tech Economic Park, Hangzhou, China, with approximately 8,411 employees and operations focused on the domestic market; it functions as a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. Notable branded products encompass Anlevolecon purean tablets and capsules; Tianbaoning ginkgo biloba preparations; Kangenbei enteritis treatments; Jinaokang omeprazole products; Jin Di compound houttuynia cordata; Jinkang Speed acetylcysteine effervescent tablets; and Zhixinping musk xixin drop pills, alongside health foods under Baozhilin, Yangyingtang, and other labels. In recent developments, its subsidiary Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd. entered a strategic supply partnership with EVA Pharma in June 2025 at CPHI China to enhance pharmaceutical supply chain resilience and accessibility in emerging markets, particularly the Middle East and Africa; the company also secured registration for Qinghouyan lozenges in May 2025 and reported a 12.3% year-over-year decline in Q1 2025 net profit.